Open heart · 2025
Efficacy and safety of myectomy and radiofrequency septal ablation for treating hypertrophic obstructive cardiomyopathy.
СтатьяНаблюдательное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bruscky Larissa Ventura Ribeiro, Valdigem Bruno Pereira, Correia Edileide de Barros, Chaccur Paulo, Vilela Andrea de Andrade, Paladino Filho Antônio Tito, Pinto Ibraim, Ramos Rui Fernando, Assef Jorge Eduardo
Аннотация
BACKGROUND: Novel treatments are needed for patients with severely symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Radiofrequency (RF) septal ablation has emerged as a promising technique for improving the left ventricular outflow tract (LVOT) gradient and alleviating symptoms, potentially achieving outcomes comparable to the gold-standard surgical myectomy.
OBJECTIVES: To compare the 1-year efficacy and safety of surgical myectomy with RF septal ablation in patients with oHCM.
METHODS: This observational, retrospective cohort study included patients aged≥18 years with oHCM and an LVOT gradient≥50 mm Hg, unresponsive to medical therapy, who underwent surgical myectomy or RF septal ablation between 2012 and 2022.
RESULTS: The mean age was 49.8±14 and 56.9±10.9 years for the myectomy and RF groups, respectively, with the same sex distribution. The proportions of patients in functional class III distributions were 54.5% and 76.1% in the myectomy and RF groups, respectively. The LVOT gradient was 108.6±49.8 and 101.1±40.3 mm Hg for the myectomy and RF groups, respectively. Procedural success, defined as a reduction in the LVOT gradient to <50 mm Hg or an improvement to functional class I or II, showed no significant difference between the groups (HR: -3.5; 95% CI: -20.2 to 13.12; p=0.673). Complications occurred in 57.6% and 4.6% of the patients in the myectomy and RF groups, respectively (p<0.001).
CONCLUSIONS: RF septal ablation and surgical myectomy demonstrated similar efficacy in reducing LVOT gradients and improving symptoms. However, RF ablation exhibited a superior safety profile.
OBJECTIVES: To compare the 1-year efficacy and safety of surgical myectomy with RF septal ablation in patients with oHCM.
METHODS: This observational, retrospective cohort study included patients aged≥18 years with oHCM and an LVOT gradient≥50 mm Hg, unresponsive to medical therapy, who underwent surgical myectomy or RF septal ablation between 2012 and 2022.
RESULTS: The mean age was 49.8±14 and 56.9±10.9 years for the myectomy and RF groups, respectively, with the same sex distribution. The proportions of patients in functional class III distributions were 54.5% and 76.1% in the myectomy and RF groups, respectively. The LVOT gradient was 108.6±49.8 and 101.1±40.3 mm Hg for the myectomy and RF groups, respectively. Procedural success, defined as a reduction in the LVOT gradient to <50 mm Hg or an improvement to functional class I or II, showed no significant difference between the groups (HR: -3.5; 95% CI: -20.2 to 13.12; p=0.673). Complications occurred in 57.6% and 4.6% of the patients in the myectomy and RF groups, respectively (p<0.001).
CONCLUSIONS: RF septal ablation and surgical myectomy demonstrated similar efficacy in reducing LVOT gradients and improving symptoms. However, RF ablation exhibited a superior safety profile.